VCBeat Health Contact Us
Home Hansoh Pharma's 4th-Gen EGFR-TKI HS-10504 Receives NMPA Breakthrough Therapy Designation for NSCLC

Hansoh Pharma's 4th-Gen EGFR-TKI HS-10504 Receives NMPA Breakthrough Therapy Designation for NSCLC

May 21, 2026 18:42 CST Updated 18:54
Hansoh Pharma

Pharmaceutical Research, Production, and Sales